E-learningSACT -KAPNCT07600853
Development and Validation of an E-learning Module on Systemic Anticancer Therapy and Its Effectiveness on the Knowledge Attitude and Practice of Nurses in Administering Systemic Anticancer Agents at a Specialized Cancer Centres in Oman.
A study testing E-Learning and No E-Learning in people with E-learning and Knowledge, run by Sultan Qaboos Comprehensive Cancer Center at 1 site in Oman.
Trial summary
Cancer is becoming more common worldwide. In countries like the United States, cases of breast and colorectal cancer have increased in recent years. A similar pattern is seen in Oman, where breast cancer is the most common cancer among women, and colorectal cancer is the most common among men. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- E-learning, Knowledge, Attitude
- What is being tested?
- E-Learning and No E-Learning
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 238 participants
- Where
- 1 siteOman
- Study dates
- 1 Jun 2026to 1 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Nurses who are willing to participate in the study
- Nurses who speaks and understand English.
- Nurses who administer systemic anti-cancer treatment in oncology units.
- Nurses who are administering systemic anticancer treatment to the adult oncology patient through IV piggyback
- Nurses who are willing to attend the orientation meeting getting familiarity with the study purpose and e- learning module.
- Nurses who completed baseline training in systemic anticancer therapy.
Who cannot join
- Nurses who are not willing to participate in the study
- Nurses who are administering systemic anticancer therapy to the pediatric patients
- Nurses who are administering systemic anticancer therapy to the non-oncology patient.
- Nurses who are not completed baseline training in systemic anticancer therapy.
- Nurses who are pregnant and breast feeding.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Namitha S Sivankutty, Masters of Science in Nursing contact
Oman1 site
Sultan Qaboos Comprehensive Cancer Care and Research Center - University Medical City
Muscat, Seeb, 123
Al Kindy, 97655101, a.alkindy@cccrc.gov.om
About this study
Cancer is becoming more common worldwide. In countries like the United States, cases of breast and colorectal cancer have increased in recent years. A similar pattern is seen in Oman, where breast cancer is the most common cancer among women, and colorectal cancer is the most common among men. As more people are diagnosed with cancer, there is a growing need for safe and effective cancer treatment.
One important type of treatment is systemic anticancer therapy (SACT), which includes medications such as chemotherapy, immunotherapy, and targeted therapy. These treatments are powerful and can cause serious side effects if not given correctly. Because of this, nurses who administer these treatments need special knowledge and skills to ensure patient safety.
Read more
This study aims to develop an online learning (e-learning) program to help nurses improve their knowledge, skills, and confidence in safely administering systemic anticancer therapy. The study will also evaluate whether this e-learning program is effective compared to routine education.
The study will be conducted in two major cancer care centers in Oman: the National Oncology Centre at Royal Hospital and the Sultan Qaboos Comprehensive Cancer Care and Research Centre. Nurses working in oncology and hematology units in these centers will be invited to participate.
Participants will be divided into two groups. One group will receive access to the e-learning program (intervention group), while the other group will continue with their usual training (control group). The assignment to these groups will be done randomly to ensure fairness.
Before starting the program, all participants will complete a questionnaire to assess their current knowledge, attitude, and practices related to systemic anticancer therapy. They will also provide basic information such as their age, years of experience, and previous training.
The e-learning program will be developed based on the learning needs of nurses and reviewed by experts in oncology to ensure accuracy and quality. Nurses in the intervention group will be given time to complete the online training.
After the training period, all participants (both groups) will complete the same questionnaire again. This will help researchers compare the results before and after the training, as well as between the two groups, to see if the e-learning program made a difference.
The study will also assess how satisfied the nurses are with the e-learning program, as learner satisfaction is important for the success of educational interventions.
Participation in this study is voluntary. All participants will provide written informed consent before joining the study. They will be informed about the purpose of the study, what they need to do, and their right to withdraw at any time without any negative consequences. All information collected will be kept confidential and used only for research purposes.
At the end of the study, nurses in the control group will also be given access to the e-learning program to ensure fairness.
The results of this study are expected to show that the e-learning program improves nurses' knowledge, attitudes, and clinical practices in administering systemic anticancer therapy. This may help improve patient safety and the quality of cancer care in Oman.
- Conditions
- E-learning, Knowledge, Attitude, Practice
- Being tested
- E-Learning, No E-Learning
- Medical subject headings
- Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
E-LearningOther
Arm Description: The intervention consists of a 20-hour E-learning certification course designed to enhance nurses' knowledge and clinical skills in systemic anti-cancer therapy administration and care. The course curriculum was developed and validated with guidance from oncology experts at the Sultan Qaboos Comprehensive Cancer Care and Research Centre and Sree Ramachandra Institute of Higher Education and Research. The content aligns with recognized international standards, including those from the United States Pharmacopeia (USP <800>), the Oncology Nursing Society Chemotherapy and Immunotherapy Guidelines (2023), the Joint Commission International Standards for Hospitals (8th Edition), and the National Institute for Occupational Safety and Health.
No E-LearningOther
Arm Description: As a participant in the control group, you will not receive the E-learning intervention during the initial phase of the study. You will continue with the standard institutional training and routine clinical practice provided at the hospital. Your participation will allow comparison between nurses who receive the intervention and those who follow the existing training system. At the completion of the study, access to the E-learning module may be provided to you as per institutional approval.
| Study group | Role | What they receive |
|---|---|---|
| Control Group: No E-Learning Intervention | Active comparator | As a participant in the control group, you will not receive the E-learning intervention during the initial phase of the study. You will continue with the standard institutional training and routine clinical practice provided at the hospital. Your participation will allow comparison between nurses who receive the intervention and those who follow the existing training system. At the completion of the study, access to the E-learning module may be provided to you as per institutional approval. Receives: Other: No E-Learning |
| Interventional Arm: Receives E-Learning Modules | Experimental | The intervention consists of a 20-hour E-learning certification course designed to enhance nurses' knowledge and clinical skills in systemic anti-cancer therapy administration and care.
The course curriculum was developed and validated with guidance from oncology experts at the Sultan Qaboos Comprehensive Cancer Care and Research Centre and Sree Ramachandra Institute of Higher Education and Research. The content aligns with recognized international standards, including those from the United States Pharmacopeia (USP <800>), the Oncology Nursing Society Chemotherapy and Immunotherapy Guidelines (2023), the Joint Commission International Standards for Hospitals (8th Edition), and the National Institute for Occupational Safety and Health. Receives: Other: E-Learning |
What is being measured
The primary outcome is the main question the study is designed to answer.
1: Knowledge regarding systemic anticancer therapy (SACT) administration
Knowledge will be assessed using a 30-item multiple-choice questionnaire developed by the researcher based on the content of the e-learning module for systemic anticancer therapy administration. The questionnaire was validated by oncology experts. Total scores range from 0 to 30, with higher scores indicating greater knowledge regarding SACT administration. Knowledge levels will be categorized as follows: Basic knowledge (0-10), Moderate knowledge (11-20), and High knowledge (21-30).
Measured: Baseline and post-intervention- (collected within one year)
Primary Outcome Measure 2: Attitude toward safe administration of systemic anticancer therapy (SACT)
Attitude will be measured using a validated structured dichotomous questionnaire assessing nurses' attitudes toward the safe administration of systemic anticancer therapy drugs. The tool was developed by a nurse researcher, and formal permission was obtained for its use in the current study.
The total attitude score ranges from 0 to 6, with higher scores indicating a more positive attitude toward safe systemic anticancer therapy (SACT) administration. Scores ranging from 0 to 3 indicate a negative attitude toward SACT administration, whereas scores above 3 indicate a positive attitude.
Previous study: https://doi.org/10.31557/apjcp.2025.26.9.3331
Measured: Baseline and post-intervention (Within 1 year)
Primary Outcome Measure 3: Practice related to systemic anticancer therapy (SACT) administration
Practice will be evaluated using the Oncology Nursing Society Clinical Practicum Checklist, a validated tool designed to assess core nursing practices related to systemic anticancer therapy administration. The checklist consists of 12 items representing key components of safe and effective SACT administration. Each item is scored dichotomously as Yes = 1 point (correct/competent practice) and No = 0 points (incorrect or incomplete practice).
Total scores range from 0 to 12, with higher scores indicating greater competence in SACT administration. Practice levels will be categorized as follows: Poor practice (0-4), Moderate practice (5-8), and Good practice (9-12).
Measured: Baseline and post-intervention (Within 1 year of data collection)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2026
- Study start1 Jun 2026 (estimated)
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for E-learningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- This study is a quasi-experimental study with non-randomized control and intervention groups. The quasi-experimental design will be used with a pre-test, post-test and a follow-up be done on nurses working in the oncology area administering systemic anticancer therapy through a learning management platform in the intervention group. For the control group two set of knowledge and practice questionaries' will be administered using on nurses working in the oncology area administering systemic anticancer therapy.
- Masking
- None (open label)
- Enrolment
- 238 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sultan Qaboos Comprehensive Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07600853
- Sponsor's protocol ID
- E learning SACT -KAP Study
- Other IDs
- CCCRC-54-2024
- Acronym
- SACT -KAP
- Status last verified
- May 2026
- First submitted
- 7 May 2026
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Validation of an E-learning Module on Systemic Anticancer Therapy and Its Effectiveness on the Knowledge Attitude and Practice of Nurses in Administering Systemic Anticancer Agents at a Specialized Cancer Centres in Oman.
- ClinicalTrials.gov ID
- NCT07600853
- Acronym / sponsor ID
- SACT -KAP / E learning SACT -KAP Study
- Conditions
- E-learning, Knowledge, Attitude, Practice
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 238 participants (estimated)
- Lead sponsor
- Sultan Qaboos Comprehensive Cancer CenterUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 1 Jun 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 22 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cancer is becoming more common worldwide. In countries like the United States, cases of breast and colorectal cancer have increased in recent years. A similar pattern is seen in Oman, where breast cancer is the most common cancer among women, and colorectal cancer is the most common among men. As more people are diagnosed with cancer, there is a growing need for safe and effective cancer treatment.
One important type of treatment is systemic anticancer therapy (SACT), which includes medications such as chemotherapy, immunotherapy, and targeted therapy. These treatments are powerful and can cause serious side effects if not given correctly. Because of this, nurses who administer these treatments need special knowledge and skills to ensure patient safety.
This study aims to develop an online learning (e-learning) program to help nurses improve their knowledge, skills, and confidence in safely administering systemic anticancer therapy. The study will also evaluate whether this e-learning program is effective compared to routine education.
The study will be conducted in two major cancer care centers in Oman: the National Oncology Centre at Royal Hospital and the Sultan Qaboos Comprehensive Cancer Care and Research Centre. Nurses working in oncology and hematology units in these centers will be invited to participate.
Participants will be divided into two groups. One group will receive access to the e-learning program (intervention group), while the other group will continue with their usual training (control group). The assignment to these groups will be done randomly to ensure fairness.
Before starting the program, all participants will complete a questionnaire to assess their current knowledge, attitude, and practices related to systemic anticancer therapy. They will also provide basic information such as their age, years of experience, and previous training.
The e-learning program will be developed based on the learning needs of nurses and reviewed by experts in oncology to ensure accuracy and quality. Nurses in the intervention group will be given time to complete the online training.
After the training period, all participants (both groups) will complete the same questionnaire again. This will help researchers compare the results before and after the training, as well as between the two groups, to see if the e-learning program made a difference.
The study will also assess how satisfied the nurses are with the e-learning program, as learner satisfaction is important for the success of educational interventions.
Participation in this study is voluntary. All participants will provide written informed consent before joining the study. They will be informed about the purpose of the study, what they need to do, and their right to withdraw at any time without any negative consequences. All information collected will be kept confidential and used only for research purposes.
At the end of the study, nurses in the control group will also be given access to the e-learning program to ensure fairness.
The results of this study are expected to show that the e-learning program improves nurses' knowledge, attitudes, and clinical practices in administering systemic anticancer therapy. This may help improve patient safety and the quality of cancer care in Oman.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study is a quasi-experimental study with non-randomized control and intervention groups. The quasi-experimental design will be used with a pre-test, post-test and a follow-up be done on nurses working in the oncology area administering systemic anticancer therapy through a learning management platform in the intervention group. For the control group two set of knowledge and practice questionaries' will be administered using on nurses working in the oncology area administering systemic anticancer therapy.
| Arm | Type | Receives |
|---|---|---|
| Control Group: No E-Learning Intervention | Active comparator | Other: No E-LearningAs a participant in the control group, you will not receive the E-learning intervention during the initial phase of the study. You will continue with the standard institutional training and routine clinical practice provided at the hospital. Your participation will allow comparison between nurses who receive the intervention and those who follow the existing training system. At the completion of the study, access to the E-learning module may be provided to you as per institutional approval. |
| Interventional Arm: Receives E-Learning Modules | Experimental | Other: E-LearningThe intervention consists of a 20-hour E-learning certification course designed to enhance nurses' knowledge and clinical skills in systemic anti-cancer therapy administration and care. The course curriculum was developed and validated with guidance from oncology experts at the Sultan Qaboos Comprehensive Cancer Care and Research Centre and Sree Ramachandra Institute of Higher Education and Research. The content aligns with recognized international standards, including those from the United States Pharmacopeia (USP <800>), the Oncology Nursing Society Chemotherapy and Immunotherapy Guidelines (2023), the Joint Commission International Standards for Hospitals (8th Edition), and the National Institute for Occupational Safety and Health. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Nurses who are willing to participate in the study
Key exclusion criteria (5 listed)
- Nurses who are not willing to participate in the study
- Nurses who are administering systemic anticancer therapy to the pediatric patients
- Nurses who are administering systemic anticancer therapy to the non-oncology patient.
- Nurses who are not completed baseline training in systemic anticancer therapy.
- Nurses who are pregnant and breast feeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| E-LearningArm Description: The intervention consists of a 20-hour E-learning certification course designed to enhance nurses' knowledge and clinical skills in systemic anti-cancer therapy administration and care. The course curriculum was developed and validated with guidance from oncology experts at the Sultan Qaboos Comprehensive Cancer Care and Research Centre and Sree Ramachandra Institute of Higher Education and Research. The content aligns with recognized international standards, including those from the United States Pharmacopeia (USP <800>), the Oncology Nursing Society Chemotherapy and Immunotherapy Guidelines (2023), the Joint Commission International Standards for Hospitals (8th Edition), and the National Institute for Occupational Safety and Health. | Other | Interventional Arm: Receives E-Learning Modules |
| No E-LearningArm Description: As a participant in the control group, you will not receive the E-learning intervention during the initial phase of the study. You will continue with the standard institutional training and routine clinical practice provided at the hospital. Your participation will allow comparison between nurses who receive the intervention and those who follow the existing training system. At the completion of the study, access to the E-learning module may be provided to you as per institutional approval. | Other | Control Group: No E-Learning Intervention |
Primary outcome
1: Knowledge regarding systemic anticancer therapy (SACT) administration
Time frame: Baseline and post-intervention- (collected within one year)
Knowledge will be assessed using a 30-item multiple-choice questionnaire developed by the researcher based on the content of the e-learning module for systemic anticancer therapy administration. The questionnaire was validated by oncology experts. Total scores range from 0 to 30, with higher scores indicating greater knowledge regarding SACT administration. Knowledge levels will be categorized as follows: Basic knowledge (0-10), Moderate knowledge (11-20), and High knowledge (21-30).
Primary Outcome Measure 2: Attitude toward safe administration of systemic anticancer therapy (SACT)
Time frame: Baseline and post-intervention (Within 1 year)
Attitude will be measured using a validated structured dichotomous questionnaire assessing nurses' attitudes toward the safe administration of systemic anticancer therapy drugs. The tool was developed by a nurse researcher, and formal permission was obtained for its use in the current study. The total attitude score ranges from 0 to 6, with higher scores indicating a more positive attitude toward safe systemic anticancer therapy (SACT) administration. Scores ranging from 0 to 3 indicate a negative attitude toward SACT administration, whereas scores above 3 indicate a positive attitude. Previous study: https://doi.org/10.31557/apjcp.2025.26.9.3331
Primary Outcome Measure 3: Practice related to systemic anticancer therapy (SACT) administration
Time frame: Baseline and post-intervention (Within 1 year of data collection)
Practice will be evaluated using the Oncology Nursing Society Clinical Practicum Checklist, a validated tool designed to assess core nursing practices related to systemic anticancer therapy administration. The checklist consists of 12 items representing key components of safe and effective SACT administration. Each item is scored dichotomously as Yes = 1 point (correct/competent practice) and No = 0 points (incorrect or incomplete practice). Total scores range from 0 to 12, with higher scores indicating greater competence in SACT administration. Practice levels will be categorized as follows: Poor practice (0-4), Moderate practice (5-8), and Good practice (9-12).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: No
Related trials for E-learning
Recruiting
Impact of an E-Learning Coaching for Parents of Young Children With Autism
Autism Spectrum Disorder
Active, not recruitingPhase 1
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
Healthy Participants
Not yet recruiting
Effectiveness of GEMPO E-Education on Fathers' Self-Efficacy and Ability in Newborn Care
Fathers' Self-Efficacy and Ability in Newborn Care
Recruiting
Effectiveness of a Combined e-Learning and Virtual Reality Training Program for Healthcare Providers in Rheumatology
Rheumatic Diseases
Recruiting
Digital Health Education to Improve Cardiovascular Health Across Different Socioeconomic Groups: e-DUCASS Advance
Cardiovascular Health, Health Literacy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Namitha S Sivankutty, Masters of Science in Nursing contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing E-Learning and No E-Learning in people with E-learning and Knowledge, run by Sultan Qaboos Comprehensive Cancer Center at 1 site in Oman.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Oman. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Namitha S Sivankutty, Masters of Science in Nursing (+96879389910, namithasivankutty@sriramachandra.edu.in), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
1: Knowledge regarding systemic anticancer therapy (SACT) administration (time frame: Baseline and post-intervention- (collected within one year)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.